Table 1.
Characteristics of the study sample and change in physical activity from before to after total joint arthroplasty, according to patient characteristics. Physical activity (PA) values are median and IQR minutes per week
| THA |
TKA |
|||||||
|---|---|---|---|---|---|---|---|---|
| n (%) | PA prior to surgery | PA post to surgery | Change in PA | n (%) | PA prior to surgery | PA post to surgery | Change in PA | |
| Total | 5,678 | 50 (0–140) | 150 (60–280) | 70 (0–170) | 11,084 | 58 (3–143) | 150 (60–280) | 76 (0–179) |
| Sex | ||||||||
| Female | 3,323 (59) | 41 (0–120) | 150 (40–240) | 68 (0–156) | 6,861 (62) | 45 (0–120) | 150 (60–240) | 74 (0–165) |
| Male | 2,355 (41) | 64 (0–173) | 180 (60–300) | 75 (0–190) | 4,223 (38) | 80 (15–180) | 180 (80–300) | 80 (0–198) |
| Age, median (IQR) | 67 (60–75) | 68 (62–75) | ||||||
| Age category | ||||||||
| Age <55 | 666 (12) | 57 (0–150) | 150 (40–300) | 60 (0–180) | 788 (7) | 60 (2–148) | 150 (60–270) | 76 (0–180) |
| Age ≥55 | 5,012 (88) | 50 (0–140) | 150 (60–280) | 70 (0–169) | 10,296 (93) | 57 (3–142) | 150 (60–280) | 76 (0–178) |
| BMI, median (IQR) a | 28 (25–32) | 30 (27–34) | ||||||
| BMI category a | ||||||||
| < 30 | 3,519 (62) | 68 (0–165) | 180 (60–300) | 70 (0–180) | 5,393 (49) | 75 (15–173) | 180 (90–300) | 80 (0–180) |
| ≥ 30 and <35 | 1,407 (25) | 33 (0–120) | 150 (30–240) | 70 (0–166) | 3,361 (30) | 50 (0–126) | 150 (60–250) | 73 (0–178) |
| ≥ 35 | 752 (13) | 17 (0–70) | 120 (0–210) | 60 (0–150) | 2,324 (21) | 30 (0–95) | 120 (20–210) | 66 (0–164) |
| Race | ||||||||
| White | 4,310 (76) | 52 (0–150) | 150 (60–280) | 70 (0–168) | 7,001 (63) | 63 (4–151) | 150 (60–300) | 72 (0–175) |
| Hispanic | 586 (10) | 34 (0–100) | 150 (50–240) | 90 (0–180) | 2,170 (20) | 45 (1–116) | 150 (60–270) | 83 (0–180) |
| Black | 512 (9) | 40 (0–115) | 150 (60–290) | 77 (0–180) | 1,035 (9) | 42 (3–108) | 150 (60–250) | 77 (0–180) |
| Asian | 187 (3) | 75 (7–150) | 150 (30–300) | 50 (0–153) | 682 (6) | 69 (10–146) | 180 (70–280) | 75 (0–175) |
| Other | 57 (1) | 48 (0–138) | 200 (80–360) | 120 (14–210) | 135 (1) | 40 (0–150) | 150 (20–270) | 80 (0–158) |
| Unknown | 26 (0.5) | 52 (8–107) | 150 (40–250) | 26 (–30–150) | 61 (0.6) | 40 (0–138) | 180 (60–300) | 80 (0–180) |
| Diabetes | 1,074 (19) | 31 (0–100) | 140 (30–240) | 70 (0–163) | 3,022 (27) | 42 (0–120) | 140 (60–250) | 70 (0–175) |
| Comorbidity a | ||||||||
| Congestive heart failure | 129 (2) | 10 (0–82) | 70 (0–210) | 30 (0–167) | 260 (2) | 34 (0–120) | 140 (40–270) | 80 (0–194) |
| Valvular disease | 203 (4) | 54 (0–140) | 150 (30–300) | 90 (0–180) | 347 (3) | 60 (3–152) | 160 (70–280) | 75 (0–165) |
| Pulmonary circulation disease | 39 (0.7) | 15 (0–105) | 100 (0–300) | 30 (0–210) | 59 (0.5) | 39 (0–110) | 100 (40–250) | 56 (0–200) |
| Peripheral vascular disease | 424 (8) | 35 (0–135) | 140 (0–275) | 55 (0–180) | 776 (7.0) | 45 (1–120) | 150 (50–280) | 82 (0–177) |
| Paralysis | 24 (0.4) | 45 (0–130) | 90 (0–225) | 0 (–29–115) | 58 (0.5) | 15 (0–85) | 60 (0–210) | 35 (0–120) |
| Other neurological disorders | 142 (3) | 45 (0–120) | 120 (40–210) | 60 (0–140) | 319 (3) | 41 (0–133) | 140 (0–210) | 50 (0–140) |
| Chronic pulmonary disease | 744 (13) | 35 (0–120) | 140 (40–260) | 70 (0–170) | 1,561 (14) | 47 (0–120) | 150 (50–240) | 70 (0–172) |
| Hypothyroidism | 658 (12) | 40 (0–121) | 150 (20–240) | 60 (0–159) | 1,398 (13) | 52 (4–140) | 150 (60–240) | 70 (0–160) |
| Renal failure | 486 (9) | 23 (0–92) | 120 (10–210) | 56 (0–144) | 1,151 (10) | 39 (0–120) | 120 (40–210) | 61 (0–150) |
| Liver disease | 111 (2) | 55 (0–173) | 180 (60–360) | 80 (0–180) | 252 (2) | 53 (4–145) | 150 (50–240) | 63 (0–150) |
| Peptic ulcer | 0 (0) | – | – | – | 3 (0.0) | 0 (0–70) | 70 (0–210) | 70 (0–140) |
| AIDS | 8 (0.1) | 104 (45–155) | 435 (270–735) | 280 (150–632) | 5 (0.0) | 13 (0–316) | 450 (450–600) | 284 (107–450) |
| Lymphoma | 21 (0.4) | 60 (23–150) | 180 (70–360) | 30 (0–230) | 25 (0.2) | 35 (17–160) | 140 (0–210) | 40 (–17–140) |
| Metastatic cancer | 19 (0.3) | 98 (20–208) | 160 (0–270) | 50 (–20–150) | 25 (0.2) | 20 (0–60) | 210 (90–300) | 129 (0–240) |
| Solid tumor w/o metastasis | 58 (1) | 19 (0–120) | 155 (40–360) | 120 (0–210) | 105 (0.9) | 65 (15–130) | 150 (90–280) | 77 (20–180) |
| Rheumatoid arthritis | 161 (3) | 27 (0–110) | 120 (10–210) | 60 (0–144) | 305 (3) | 47 (0–120) | 150 (70–270) | 83 (0–180) |
| Coagulopathy | 109 (2) | 63 (0–150) | 140 (0–280) | 30 (–1–145) | 195 (2) | 56 (6–120) | 120 (20–280) | 53 (–10–151) |
| Weight loss | 48 (0.8) | 5 (0–62) | 145 (15–280) | 80 (0–225) | 78 (0.7) | 47 (8–135) | 150 (60–280) | 91 (0–210) |
| Fluid and electrolyte disorders | 304 (5) | 35 (0–120) | 150 (50–275) | 83 (0–178) | 635 (6) | 60 (7–150) | 150 (60–280) | 80 (0–177) |
| Chronic blood loss anemia | 169 (3) | 17 (0–72) | 120 (30–240) | 90 (0–160) | 395 (4) | 51 (10–120) | 180 (70–300) | 98 (1–184) |
| Deficiency anemias | 586 (10) | 35 (0–112) | 145 (40–250) | 79 (0–180) | 1,137 (10) | 49 (0–125) | 150 (60–250) | 76 (0–169) |
| Alcohol abuse | 119 (2) | 35 (0–119) | 150 (20–300) | 61 (0–168) | 197 (2) | 60 (12–160) | 160 (60–280) | 64 (0–154) |
| Drug abuse | 76 (1) | 8 (0–70) | 140 (0–275) | 70 (0–185) | 97 (0.9) | 53 (0–148) | 150 (20–240) | 44 (–1–147) |
| Psychoses | 403 (7) | 30 (0–105) | 120 (0–210) | 48 (0–137) | 857 (8) | 41 (0–118) | 150 (40–240) | 70 (0–159) |
| Depression | 259 (5) | 30 (0–124) | 150 (20–270) | 77 (0–188) | 561 (5) | 43 (0–120) | 150 (60–240) | 73 (0–179) |
| Hypertension | 2,957 (52) | 39 (0–120) | 150 (40–250) | 70 (0–160) | 6,494 (59) | 50 (0–135) | 150 (60–270) | 73 (0–173) |
THA: total hip arthroplasty; TKA: total knee arthroplasty; BMI: body mass index; AIDS: acquired immunodeficiency syndrome; PA: physical activity; IQR: interquartile range.
a
Missing data: comorbidity indicators (13.2%, n = 752) in THA cases; BMI (0.1%, n = 6) and comorbidity indicators (15.1%, n = 1,678) in TKA.